@article{oai:nagasaki-u.repo.nii.ac.jp:00016419,
 author = {Yamamoto, Kazuko and Yanagihara, Katsunori and Sugahara, Kazuyuki and Imamura, Yoshifumi and Seki, Masafumi and Izumikawa, Koichi and Kakeya, Hiroshi and Yamamoto, Yoshihiro and Hirakata, Yoichi and Kamihira, Shimeru and Kohno, Shigeru},
 issue = {8},
 journal = {Antimicrobial agents and chemotherapy},
 month = {Aug},
 note = {We evaluated the potency of garenoxacin in selecting resistant Streptococcus pneumoniae mutants by determining its mutant prevention concentration, using strains with and without topoisomerase gene mutations, and compared its potency to that of other quinolones. Garenoxacin had a significantly greater potency against pneumococci, including strains containing topoisomerase mutations. Genetic analysis of the S. pneumoniae mutants created by garenoxacin revealed that the gyrA gene was a primary target of garenoxacin., Antimicrobial agents and chemotherapy, 53(8), pp.3572-3575; 2009},
 pages = {3572--3575},
 title = {In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.},
 volume = {53},
 year = {2009}
}